Blogs
ICYMI: The Biosimilar "Buy In"
The landscape of biosimilars is vast. This year alone we are expecting 17 biosimilars in rheumatology. While some pharmaceutical company and payer contracts are still under negotiation, we need to start preparing ourselves and our patients. Drs. Jack Cush and Arthur Kavanuagh shared insights into these key discussions during RheumNow Live 2023.An Opportunity to Say Yes
Often, I am asked why I get to do all the fun stuff in rheumatology like blogging, traveling, meeting and interviewing interesting people, and collaborating in cool projects. How do I get those opportunities? Why am I involved in so many things? The answer: because I say, “Yes!”No is a complete sentence
No is a complete sentence. For context, I am a "yes" person, and I always have been.Giving Good Care in Diversity takes Time
Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes.